Search alternatives:
significantly estimated » significantly mitigated (Expand Search), significant estimates (Expand Search), significantly overestimated (Expand Search)
barrier decrease » barrier disease (Expand Search), marked decrease (Expand Search), barrier creates (Expand Search)
larger decrease » marked decrease (Expand Search)
Showing 21 - 40 results of 9,692 for search '(( significantly estimated decrease ) OR ( significant ((barrier decrease) OR (larger decrease)) ))', query time: 1.19s Refine Results
  1. 21
    Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15.

    Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15. by Therese M. Gilligan (7460906)

    Published 2019
    Save to List
    Saved in:
  2. 22
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 23
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 24
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 25
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 26
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 27
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 28
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 29
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 30
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 31
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 32
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 33
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 34
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 35
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 36
    Importance ranking and significance test results.

    Importance ranking and significance test results. by Yumei Liang (8661069)

    Published 2021
    Save to List
    Saved in:
  17. 37
    Number of patients with a significant increase or significant decrease between the baseline measurement (SCr-BL) and the creatinine measurement at emergency department presentation (SCr-ED).

    Number of patients with a significant increase or significant decrease between the baseline measurement (SCr-BL) and the creatinine measurement at emergency department presentation... by M. S. A. Niemantsverdriet (11886431)

    Published 2021
    Save to List
    Saved in:
  18. 38
    The distribution of <i>Giardia duodenalis</i> assemblages in domestic and wild populations of nonhuman mammalian species with a larger number of isolates.

    The distribution of <i>Giardia duodenalis</i> assemblages in domestic and wild populations of nonhuman mammalian species with a larger number of isolates. by Kareem Hatam-Nahavandi (7384790)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 39
    Ordination of butterfly community composition change through time.

    Ordination of butterfly community composition change through time. by Nicole B. Kucherov (11558817)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  20. 40
    Conceptual framework of relationships between remittances and other individual, household and community-level factors and outcome measures, with potential confounders and unobservable variables.

    Conceptual framework of relationships between remittances and other individual, household and community-level factors and outcome measures, with potential confounders and unobserva... by Chelsea Ducille (21540080)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: